Articles with public access mandates - Meral BeksacLearn more
Not available anywhere: 5
Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 …
MA Dimopoulos, E Terpos, M Boccadoro, S Delimpasi, M Beksac, ...
The Lancet Oncology 22 (6), 801-812, 2021
Mandates: Government of Spain
Consolidation and maintenance in newly diagnosed multiple myeloma
P Sonneveld, MA Dimopoulos, M Beksac, B van der Holt, S Aquino, ...
Journal of Clinical Oncology 39 (32), 3613-3622, 2021
Mandates: Dutch Cancer Society
A novel hypothesis: certain KIR/cognate ligand containing genotypes differ in frequency among patients with myeloma and have an effect on age of disease onset
M Beksac, HY Akin, GC Seval, PY Mesutoglu, RG Anliacik, E Anliacik, ...
Clinical Lymphoma Myeloma and Leukemia 23 (5), 394-400. e1, 2023
Mandates: Scientific and Technological Research Council of Turkey
Prognostic impact of early‐versus‐late responses to different induction regimens in patients with myeloma undergoing autologous hematopoietic cell transplantation: Results from …
L Garderet, G Sbianchi, S Iacobelli, D Blaise, JL Byrne, P Remenyi, ...
European journal of haematology 106 (5), 708-715, 2021
Mandates: National Institute for Health Research, UK
A Bottom-Up Proteomic Approach in Bone Marrow Plasma Cells of Newly Diagnosed Multiple Myeloma Patients
B Ayhan, SK Turan, NP Barkan, K Dalva, M Beksaç, DÖ Demiralp
Current Proteomics 18 (5), 730-741, 2021
Mandates: Scientific and Technological Research Council of Turkey
Available somewhere: 23
The shaping of modern human immune systems by multiregional admixture with archaic humans
L Abi-Rached, MJ Jobin, S Kulkarni, A McWhinnie, K Dalva, L Gragert, ...
Science 334 (6052), 89-94, 2011
Mandates: US National Institutes of Health
Management of treatment-emergent peripheral neuropathy in multiple myeloma
PG Richardson, M Delforge, M Beksaç, P Wen, JL Jongen, O Sezer, ...
Leukemia 26 (4), 595-608, 2012
Mandates: US National Institutes of Health
IMWG consensus on maintenance therapy in multiple myeloma
H Ludwig, BGM Durie, P McCarthy, A Palumbo, J San Miguel, B Barlogie, ...
Blood, The Journal of the American Society of Hematology 119 (13), 3003-3015, 2012
Mandates: US National Institutes of Health
Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel
J Caers, B Paiva, E Zamagni, X Leleu, J Bladé, SY Kristinsson, ...
Journal of hematology & oncology 11, 1-10, 2018
Mandates: National Fund for Scientific Research, Belgium
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group
P Moreau, SK Kumar, J San Miguel, F Davies, E Zamagni, N Bahlis, ...
The Lancet Oncology 22 (3), e105-e118, 2021
Mandates: National Natural Science Foundation of China
Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set
A Chari, MK Samur, J Martinez-Lopez, G Cook, N Biran, K Yong, ...
Blood, The Journal of the American Society of Hematology 136 (26), 3033-3040, 2020
Mandates: US National Institutes of Health, US Department of Veterans Affairs
Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment
PG Richardson, VTM Hungria, SS Yoon, M Beksac, MA Dimopoulos, ...
Blood, The Journal of the American Society of Hematology 127 (6), 713-721, 2016
Mandates: US National Institutes of Health
Central nervous system involvement by multiple myeloma: a multi‐institutional retrospective study of 172 patients in daily clinical practice
A Jurczyszyn, N Grzasko, A Gozzetti, J Czepiel, A Cerase, V Hungria, ...
American journal of hematology 91 (6), 575-580, 2016
Mandates: US National Institutes of Health
Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network
H Ludwig, M Delforge, T Facon, H Einsele, F Gay, P Moreau, ...
Leukemia, 1-46, 2017
Mandates: Cancer Research UK
Expert review on soft‐tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations
L Rosiñol, M Beksac, E Zamagni, NWCJ Van de Donk, KC Anderson, ...
British journal of haematology 194 (3), 496-507, 2021
Mandates: Government of Spain
HNRNPA2B1 promotes multiple myeloma progression by increasing AKT3 expression via m6A-dependent stabilization of ILF3 mRNA
F Jiang, X Tang, C Tang, Z Hua, M Ke, C Wang, J Zhao, S Gao, ...
Journal of hematology & oncology 14, 1-5, 2021
Mandates: US National Institutes of Health, National Natural Science Foundation of China
Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS)
CO Landgren, A Chari, YC Cohen, A Spencer, P Voorhees, JA Estell, ...
Leukemia 34 (7), 1840-1852, 2020
Mandates: US National Institutes of Health
COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network
H Ludwig, P Sonneveld, T Facon, J San-Miguel, H Avet-Loiseau, M Mohty, ...
The Lancet Haematology 8 (12), e934-e946, 2021
Mandates: Cancer Research UK
Insights on multiple myeloma treatment strategies
MV Mateos, H Ludwig, A Bazarbachi, M Beksac, J Bladé, M Boccadoro, ...
Hemasphere 3 (1), e163, 2019
Mandates: National Institute for Health Research, UK
CHEK1 and circCHEK1_246aa evoke chromosomal instability and induce bone lesion formation in multiple myeloma
C Gu, W Wang, X Tang, T Xu, Y Zhang, M Guo, R Wei, Y Wang, ...
Molecular Cancer 20 (1), 84, 2021
Mandates: US National Institutes of Health, National Natural Science Foundation of China
Publication and funding information is determined automatically by a computer program